BlackRock’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$295M Buy
6,066,358
+3,452,819
+132% +$168M 0.01% 1371
2025
Q1
$88.9M Sell
2,613,539
-145,787
-5% -$4.96M ﹤0.01% 2048
2024
Q4
$109M Sell
2,759,326
-35,973
-1% -$1.42M ﹤0.01% 2019
2024
Q3
$131M Buy
2,795,299
+17,515
+0.6% +$823K ﹤0.01% 1909
2024
Q2
$150M Buy
2,777,784
+231,423
+9% +$12.5M ﹤0.01% 1778
2024
Q1
$174M Buy
2,546,361
+29,875
+1% +$2.04M ﹤0.01% 1725
2023
Q4
$158M Sell
2,516,486
-196,724
-7% -$12.3M ﹤0.01% 1788
2023
Q3
$123M Sell
2,713,210
-5,365
-0.2% -$244K ﹤0.01% 1854
2023
Q2
$153M Sell
2,718,575
-80,006
-3% -$4.49M ﹤0.01% 1766
2023
Q1
$127M Buy
2,798,581
+168,844
+6% +$7.64M ﹤0.01% 1848
2022
Q4
$107M Buy
2,629,737
+283,153
+12% +$11.5M ﹤0.01% 1935
2022
Q3
$153M Buy
2,346,584
+194,458
+9% +$12.7M 0.01% 1662
2022
Q2
$131M Sell
2,152,126
-126,648
-6% -$7.7M ﹤0.01% 1835
2022
Q1
$143M Buy
2,278,774
+1,007,246
+79% +$63.2M ﹤0.01% 1879
2021
Q4
$96.4M Buy
1,271,528
+142,244
+13% +$10.8M ﹤0.01% 2222
2021
Q3
$126M Buy
1,129,284
+78,736
+7% +$8.81M ﹤0.01% 2049
2021
Q2
$170M Sell
1,050,548
-239,787
-19% -$38.8M ﹤0.01% 1880
2021
Q1
$157M Buy
1,290,335
+117,076
+10% +$14.3M ﹤0.01% 1879
2020
Q4
$180M Buy
1,173,259
+19,416
+2% +$2.97M 0.01% 1689
2020
Q3
$96.5M Buy
1,153,843
+141,026
+14% +$11.8M ﹤0.01% 1880
2020
Q2
$74.4M Buy
1,012,817
+399,288
+65% +$29.3M ﹤0.01% 2009
2020
Q1
$26M Sell
613,529
-15,028
-2% -$637K ﹤0.01% 2436
2019
Q4
$38.3M Buy
628,557
+12,827
+2% +$781K ﹤0.01% 2497
2019
Q3
$25.2M Buy
615,730
+20,397
+3% +$836K ﹤0.01% 2660
2019
Q2
$28M Sell
595,333
-5,148
-0.9% -$242K ﹤0.01% 2641
2019
Q1
$21.5M Sell
600,481
-38,754
-6% -$1.38M ﹤0.01% 2699
2018
Q4
$18.3M Sell
639,235
-70,408
-10% -$2.01M ﹤0.01% 2759
2018
Q3
$31.5M Buy
709,643
+116,116
+20% +$5.15M ﹤0.01% 2612
2018
Q2
$34.9M Buy
593,527
+21,309
+4% +$1.25M ﹤0.01% 2541
2018
Q1
$26.2M Buy
572,218
+19,660
+4% +$899K ﹤0.01% 2609
2017
Q4
$13M Buy
552,558
+549,254
+16,624% +$12.9M ﹤0.01% 2988
2017
Q3
$59K Buy
+3,304
New +$59K ﹤0.01% 4383